Phase 1 N=36 A Study in Healthy Japanese Men to Test How Well Different Doses of BI 3006337 Are Tolerated
Healthy
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAE) — 4; 4; 2; 2 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=130 Effects of E-Cigarette Flavors on Adults TCORS 2.0
Nicotine Use Disorder
Primary: Change Score in Liking/Wanting of E-cigarette — -1.06; -5.59; -7.14; -7.63 units on scale
Phase 1 N=24 A Study in Healthy People to Compare 2 Different Formulations of BI 1015550 Taken With or Without Food
Healthy
Primary: Area Under the Concentration-time Curve of BI 1015550 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 2290; 2740; 3000…
Phase 1 N=25 A Study to Evaluate Two Vonoprazan Orally Disintegrating Tablet Formulations Administered Without Water or Mixed With Water and Administered Via a Syringe Relative to the Vonoprazan Tablet in Healthy Participants
Healthy Volunteers
Primary: Maximum Observed Drug Concentration (Cmax) of Vonoprazan — 6.11; 5.81; 5.46; 5.72 nanogram per milliliter (ng/mL)
Phase 1 N=76 A Study Assessing the Safety of Oral ATH-399A in Healthy Adult Participants
Healthy Volunteers
Primary: Number of TEAEs — 4; 2; 1; 3 Treatment Emergent Adverse Event
Phase 1 N=24 Safety and Virologic Effect of a Human Monoclonal Antibody (VRC01) Administered Intravenously to Adults During Early Acute HIV Infection
HIV Infections
Primary: Number of Participants With Grade 3 or Greater mAb-related Reactogenicity and mAb-related Adverse Events (AEs) — 0; 0; 1 Participants
Phase 1 N=40 Phase 1 Study of E7090 in Subjects With Solid Tumor
Tumors
Primary: Part 1: Number of Participants With Dose-limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
Phase 1 N=24 HYHOPE: De-intensified Hypofractionated Radiation Therapy for HPV-associated Oropharynx Cancer
Human Papillomavirus-Related Carcinoma · Oropharyngeal Cancer
Primary: Maximally Tolerated Dose/Fractionation of Hypofractionated Radiation Therapy — 0 Participants
Phase 1 N=18 Evaluation of Vamorolone CYP3A4 Induction on Midazolam (a Sensitive CYP 3A4 Substrate) Pharmacokinetics
Drug Interaction
Primary: AUC0-tlast of Midazolam — 34331.8; 28619.6 h*pg/ml
Phase 1 N=3 Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961
Chronic Lymphocytic Leukemia
Primary: Number of Treatment-emergent Adverse Events as Assessed by CTCAE v4.0 — 1; 0; 0; 0 Adverse Events
Phase 1 N=113 A Study of Imlunestrant (LY3484356) in Female Healthy Participants
Healthy
Primary: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Repaglinide (Cohort 1) — 13.0; 13.6 nanogram*hour per…
Phase 1 N=82 A Study of LY3484356 in Healthy Female Participants
Healthy
Primary: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of LY3484356 (Cohort 1) — 1810; 4350 nanogram*hour per milliliter…
Phase 1 N=16 A Study of Effects of Selpercatinib (LY3527723) on Repaglinide in Healthy Participants
Healthy
Primary: Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Last Observed Non-zero Concentration (AUC0-t) of Repaglinide — 9.409; 26.87…
Phase 1 N=38 MitoQ for the Treatment of Metabolic Dysfunction in Asthma
Asthma · Obesity
Primary: Change in Airway Reactivity — 0; -0.8 μg methacholine — p=0.81
Phase 1 N=6 Phase 1b MMV367 PK/PD and Safety in Healthy Adult Volunteers Experimentally Infected With Blood Stage P. Falciparum
Infections · Vector Borne Diseases · Systemic Inflammatory Response Syndrome
Primary: Emax — 0.35 Maximum clearance rate (1/hour)